VIRX Viracta Therapeutics
- 0.177
- +0.016+9.94%
- 0.175
- -0.002-1.07%
Viracta Therapeutics News
Viracta Therapeutics Explores Strategic Options After NAVAL-1 Closure
12 Health Care Stocks Moving In Friday's Pre-Market Session
Deal Dispatch: Party City Wraps Up, Big Lots Goes Bust, The Container Store Continues
Masimo To Rally More Than 13%? Here Are 5 Top Analyst Forecasts For Friday
Rodman & Renshaw Downgrades Viracta Therapeutics(VIRX.US) to Hold Rating, Cuts Target Price to $0.25
Rodman & Renshaw Downgrades Viracta Therapeutics to Neutral
Constellium, Viracta Therapeutics And 3 Stocks To Watch Heading Into Friday
Stocks to Watch: Grid Dynamics, Viracta Therapeutics, Martin Midstream
Viracta Therapeutics Ends Naval-1 Clinical Trial and Is Exploring Strategic Alternatives
Express News | Viracta Therapeutics Inc - Potential Alternatives Include Merger, Licensing Agreement, Sale
Express News | Viracta Therapeutics Inc - Closure of Trial Not Due to New Safety Finding
Express News | Viracta Therapeutics Announces Closure of Naval-1 Clinical Trial and Exploration of Strategic Alternatives
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Trending Stocks Today | CN Energy Surges 94.04% Pre-Market
Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Express News | Viracta Therapeutics Inc - Receives Notice of Non-Compliance From Nasdaq
Viracta Therapeutics Is Maintained at Outperform by RBC Capital
RBC Cuts Price Target on Viracta Therapeutics to $2 From $4, Keeps Outperform, Speculative Risk
Viracta Therapeutics | 10-Q: Q3 2024 Earnings Report
Viracta Therapeutics | 8-K: Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
No Data